STEPWISE Parkinson: A Smartphone Based Exercise Solution for Patients With Parkinson's Disease (STEPWISE)
Primary Purpose
Movement Disorders, Parkinson Disease
Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Step count increase with the use of a motivational smartphone application
Sponsored by
About this trial
This is an interventional treatment trial for Movement Disorders focused on measuring Physical activity, Walking, Exercise, Parkinson Disease, Locomotion, Motivational application
Eligibility Criteria
Inclusion Criteria:
- idiopathic PD
- Hoehn and Yahr 1-3
- able to understand the Dutch language
- able to walk independently
- equal to or less than 120 minutes of sports/outdoor activities per day (question 5-28 LASA Physical Activity Questionnaire (LAPAQ))
- less than 7,000 steps/day during 1-month baseline (week -4 until 0)
Exclusion Criteria:
- weekly falls in the previous 3 months
- medical conditions that hamper mobility other than PD
- living in a nursing home
- cognitive impairments that hamper use of the motivational app (subjective evaluation by the assessor)
- not in the possession of a suitable smartphone (Iphone 5S or newer with iOS 10 or higher or Android 4.1 or newer)
Sites / Locations
- Radboud university medical centerRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Active Comparator
Arm Label
Very high dose
High dose
Intermediate dose
Active controls
Arm Description
Very large proportional increase in stepcount relative to baseline stepcount.
Large proportional increase in stepcount relative to baseline stepcount.
Medium proportional increase in stepcount relative to baseline stepcount.
Small proportional increase in stepcount relative to baseline stepcount.
Outcomes
Primary Outcome Measures
Mean change in step count per day
Mean change in step count per day as measured continuously with the participant's smartphone from baseline (week -4 to 0) to follow-up (week 49-52). Higher scores indicate more physical activity (steps).
Secondary Outcome Measures
Change in physical fitness (6MWT)
Change from baseline in meters walked during the six minute walk test (6MWT) at week 53 (follow-up). Higher scores indicate better function.
Change in physical fitness (VO2max)
Change from baseline in VO2max in ml/kg/min assessed by a maximal aerobic exercise test on a cycle ergometer at follow-up (week 53). Higher scores indicate better function. Performed in a subgroup of 100 participants.
Change in Parkinson's Disease symptoms (MDS-UPDRS)
Change from baseline in the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) at 53 weeks (follow-up). Range 0-199. Higher scores indicate worse function.
Change in mobility (TUG)
Change from baseline in the time (seconds) needed to complete the Timed Up and Go Test (TUG) at 53 weeks (follow-up). Higher scores indicate worse function.
Change in balance (Mini-BestTest)
Change from baseline on the Mini-BestTest at 53 weeks (follow-up).Range 0-28. Higher scores indicate better function.
Change in gait speed (10MWT)
Change from baseline in gait speed (m/s) as assessed by the 10 meter walk test (10MWT). Higher scores indicate better function.
Change in fear of falling (FES-I)
Change from baseline on the Dutch version of the Falls Efficacy Scale International at 53 weeks (follow-up). Range 16-64. Higher scores indicate higher fear of falling.
Number of falls and near-falls (monthly fall diary)
Number of falls and near-falls reported monthly by the participants in a fall diary drafted according to the European Physiotherapy guideline for Parkinson's Disease.
Change in handgrip strength
Change from baseline in hand grip strength (kg) as assessed with a dynamometer (best out of three attempts).
Change in self-reported physical activity level (LAPAQ)
Change from baseline on the Longitudinal Aging Study Amsterdam (LASA) physical Activity Questionnaire (LAPAQ). Higher scores indicate a higher physical activity level.
Change in cognition (MOCA)
Change from baseline on the Montreal Cognitive Assessement (MOCA) score at 53 weeks (follow-up). Range 0-30. Higher scores indicate better cognition.
Change in depression and anxiety (HADS)
Change from baseline on the Hospital Anxiety and Depression Scale (HADS) at 53 weeks (follow-up). Range 0-42. Higher scores indicate worse function.
Change in apathy (AES-12PD)
Change from baseline on the Apathy Evaluation Scale (AES-12PD) at 53 weeks (follow-up). Range 12-48. Higher scores indicate better function.
Change in fatigue (FSS)
Change from baseline on the Fatigue Severity Scale (FSS) at 53 weeks (follow-up). Range 1-7. Higher scores indicate worse function.
Change in severity of sleep problems and daytime sleepiness (SCOPA-SLEEP)
Change from baseline on the Scales for Outcomes in Parkinson's Disease - Sleep (SCOPA-Sleep) questionnaire at 53 weeks (follow-up).
Change in autonomic dysfunction (SCOPA-AUT)
Change from baseline on the Scales for Outcomes in Parkinson's Disease - autonomic questionnaire (SCOPA-AUT) at 53 weeks (follow-up).
Change in Health related quality of life (PDQ-39)
Change from baseline on the Health related quality of life (PDQ-39) questionnaire at 53 weeks (follow-up). Range 0-100. Higher scores indicate better function.
Perceived effect of intervention (GPE)
Perceived effect of intervention as assessed by the Global Perceived effect (GPE) questionnaire (7-point scale) at 53 weeks (follow-up). Range 1-7. Higher scores indicate higher perceived effect.
System Usability (SUS)
Usability of the STEPWISE application as assessed by the Dutch version of the System Usability Scale (SUS) at 53 weeks (follow-up). Range 0-100. Higher scores indicate better usability.
Perceived physical ability (LIVAS)
Change from baseline on the percieved physical ability scale (Lichamelijke Vaardigheden Schaal; LIVAS) at 53 weeks (follow-up). Range 10-50. Higher scores indicate higher perceived phisical ability.
Full Information
NCT ID
NCT04848077
First Posted
April 13, 2021
Last Updated
February 23, 2023
Sponsor
Radboud University Medical Center
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Massachusetts General Hospital, Hogeschool van Arnhem en Nijmegen (HAN), Canisius-Wilhelmina Hospital, IJsfontein Health BV
1. Study Identification
Unique Protocol Identification Number
NCT04848077
Brief Title
STEPWISE Parkinson: A Smartphone Based Exercise Solution for Patients With Parkinson's Disease
Acronym
STEPWISE
Official Title
STEPWISE Parkinson: A Smartphone Based, Titrated Exercise Solution for Patients With Parkinson's Disease in Daily Life
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 18, 2021 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
July 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Massachusetts General Hospital, Hogeschool van Arnhem en Nijmegen (HAN), Canisius-Wilhelmina Hospital, IJsfontein Health BV
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to investigate whether a smartphone app can increase physical activity in patients with Parkinson's Disease in daily life for a long period of time (12 months).
Detailed Description
Rationale: Exercise affords health benefits for people with Parkinson's disease (PD), but implementing exercise in daily life remains challenging. Moreover, many training programs are not very scalable. The investigators take an important step forward by developing and studying an innovative and fully decentralized smartphone-based program to increase long-term physical activity in people with PD in daily life.
Objective: The aim of this study is to investigate whether a smartphone app can increase physical activity in PD patients for a long period of time (12 months). The secondary aim is to test the potential group effect on physical fitness, motor- and non-motor symptoms. Thirdly, we aim to investigate whether there is a dose-response relationship between amount of physical activity and physical fitness, motor- and non-motor functioning.
Study design: Double-blind randomized controlled trial.
Study population: A total of 452 Dutch patients with PD who have no other medical conditions that markedly hamper mobility other than PD, no cognitive impairments that make it difficult to use a game on the smartphone and possess a suitable smartphone, will be recruited.
Intervention: Participants will be randomized to a group that will be motivated to increase their physical activity level to a small, medium, large or very large degree with respect to their own baseline level.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Movement Disorders, Parkinson Disease
Keywords
Physical activity, Walking, Exercise, Parkinson Disease, Locomotion, Motivational application
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
452 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Very high dose
Arm Type
Experimental
Arm Description
Very large proportional increase in stepcount relative to baseline stepcount.
Arm Title
High dose
Arm Type
Experimental
Arm Description
Large proportional increase in stepcount relative to baseline stepcount.
Arm Title
Intermediate dose
Arm Type
Experimental
Arm Description
Medium proportional increase in stepcount relative to baseline stepcount.
Arm Title
Active controls
Arm Type
Active Comparator
Arm Description
Small proportional increase in stepcount relative to baseline stepcount.
Intervention Type
Behavioral
Intervention Name(s)
Step count increase with the use of a motivational smartphone application
Intervention Description
All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).
Primary Outcome Measure Information:
Title
Mean change in step count per day
Description
Mean change in step count per day as measured continuously with the participant's smartphone from baseline (week -4 to 0) to follow-up (week 49-52). Higher scores indicate more physical activity (steps).
Time Frame
Week -4 until 0 and week 49 until 52
Secondary Outcome Measure Information:
Title
Change in physical fitness (6MWT)
Description
Change from baseline in meters walked during the six minute walk test (6MWT) at week 53 (follow-up). Higher scores indicate better function.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in physical fitness (VO2max)
Description
Change from baseline in VO2max in ml/kg/min assessed by a maximal aerobic exercise test on a cycle ergometer at follow-up (week 53). Higher scores indicate better function. Performed in a subgroup of 100 participants.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in Parkinson's Disease symptoms (MDS-UPDRS)
Description
Change from baseline in the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) at 53 weeks (follow-up). Range 0-199. Higher scores indicate worse function.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in mobility (TUG)
Description
Change from baseline in the time (seconds) needed to complete the Timed Up and Go Test (TUG) at 53 weeks (follow-up). Higher scores indicate worse function.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in balance (Mini-BestTest)
Description
Change from baseline on the Mini-BestTest at 53 weeks (follow-up).Range 0-28. Higher scores indicate better function.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in gait speed (10MWT)
Description
Change from baseline in gait speed (m/s) as assessed by the 10 meter walk test (10MWT). Higher scores indicate better function.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in fear of falling (FES-I)
Description
Change from baseline on the Dutch version of the Falls Efficacy Scale International at 53 weeks (follow-up). Range 16-64. Higher scores indicate higher fear of falling.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Number of falls and near-falls (monthly fall diary)
Description
Number of falls and near-falls reported monthly by the participants in a fall diary drafted according to the European Physiotherapy guideline for Parkinson's Disease.
Time Frame
Every four weeks after start of the intervention (at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 weeks).
Title
Change in handgrip strength
Description
Change from baseline in hand grip strength (kg) as assessed with a dynamometer (best out of three attempts).
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in self-reported physical activity level (LAPAQ)
Description
Change from baseline on the Longitudinal Aging Study Amsterdam (LASA) physical Activity Questionnaire (LAPAQ). Higher scores indicate a higher physical activity level.
Time Frame
Week -4 (screening), week 0 (baseline) and week 53 (follow-up)
Title
Change in cognition (MOCA)
Description
Change from baseline on the Montreal Cognitive Assessement (MOCA) score at 53 weeks (follow-up). Range 0-30. Higher scores indicate better cognition.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in depression and anxiety (HADS)
Description
Change from baseline on the Hospital Anxiety and Depression Scale (HADS) at 53 weeks (follow-up). Range 0-42. Higher scores indicate worse function.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in apathy (AES-12PD)
Description
Change from baseline on the Apathy Evaluation Scale (AES-12PD) at 53 weeks (follow-up). Range 12-48. Higher scores indicate better function.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in fatigue (FSS)
Description
Change from baseline on the Fatigue Severity Scale (FSS) at 53 weeks (follow-up). Range 1-7. Higher scores indicate worse function.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in severity of sleep problems and daytime sleepiness (SCOPA-SLEEP)
Description
Change from baseline on the Scales for Outcomes in Parkinson's Disease - Sleep (SCOPA-Sleep) questionnaire at 53 weeks (follow-up).
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in autonomic dysfunction (SCOPA-AUT)
Description
Change from baseline on the Scales for Outcomes in Parkinson's Disease - autonomic questionnaire (SCOPA-AUT) at 53 weeks (follow-up).
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Change in Health related quality of life (PDQ-39)
Description
Change from baseline on the Health related quality of life (PDQ-39) questionnaire at 53 weeks (follow-up). Range 0-100. Higher scores indicate better function.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Perceived effect of intervention (GPE)
Description
Perceived effect of intervention as assessed by the Global Perceived effect (GPE) questionnaire (7-point scale) at 53 weeks (follow-up). Range 1-7. Higher scores indicate higher perceived effect.
Time Frame
At week 53 (follow-up)
Title
System Usability (SUS)
Description
Usability of the STEPWISE application as assessed by the Dutch version of the System Usability Scale (SUS) at 53 weeks (follow-up). Range 0-100. Higher scores indicate better usability.
Time Frame
At week 53 (follow-up)
Title
Perceived physical ability (LIVAS)
Description
Change from baseline on the percieved physical ability scale (Lichamelijke Vaardigheden Schaal; LIVAS) at 53 weeks (follow-up). Range 10-50. Higher scores indicate higher perceived phisical ability.
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Other Pre-specified Outcome Measures:
Title
STEPWISE Parkinson smartphone application data
Description
User data from the STEPWISE smartphone application will be collected, including number of interactions with the app and the total time the application was used.
Time Frame
From baseline (week 0) to follow-up (week 53)
Title
Adherence to the intervention
Description
Adherence to the study intervention as indicated by the number of days the STEPWISE app was used.
Time Frame
From baseline (week 0) to follow-up (week 53)
Title
Barriers and motivators to engage in exercise/physical activity at baseline and follow-up
Description
Barriers and motivators to engage in exercise/physical activity reported on the self-developed Barriers and Motivators questionnaire at week 0 (baseline) and week 53 (follow-up).
Time Frame
Week 0 (baseline) and week 53 (follow-up)
Title
Exploratory measurement of physical acitivity with wearable sensor
Description
Movement data captured with a 6-axis inertial movement sensor (Axivity AX6).
Time Frame
From week 0 (baseline) to week 1 and from week 52 to week 53 (follow-up)
Title
Parkinson's disease symptoms monitored with the mPower app
Description
Parkinson's disease symptoms monitored remotely with the mPower smartphone app.
Time Frame
Every three months from week 0 (baseline) to week 53 (follow-up)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
idiopathic PD
Hoehn and Yahr 1-3
able to understand the Dutch language
able to walk independently
equal to or less than 120 minutes of sports/outdoor activities per day (question 5-28 LASA Physical Activity Questionnaire (LAPAQ))
less than 7,000 steps/day during 1-month baseline (week -4 until 0)
Exclusion Criteria:
weekly falls in the previous 3 months
medical conditions that hamper mobility other than PD
living in a nursing home
cognitive impairments that hamper use of the motivational app (subjective evaluation by the assessor)
not in the possession of a suitable smartphone (Iphone 5S or newer with iOS 10 or higher or Android 4.1 or newer)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sabine Schootemeijer, MSc
Phone
00316 50155754
Email
sabine.schootemeijer@radboudumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bastiaan Bloem, Prof. Dr.
Organizational Affiliation
Radboudumc Department of Neurology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Radboud university medical center
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6500 HB
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabine Schootemeijer, MSc.
Phone
00316 50155754
Email
sabine.schootemeijer@radboudumc.nl
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
We will make relevant and anonymised data available in a validated database.
IPD Sharing Time Frame
After publication of the main results of our trial.
IPD Sharing Access Criteria
Access to the data is restricted, meaning that researchers who are interested in re-use of the data are asked to contact the central contact person for permission. Approval is given after a signed agreement.
Learn more about this trial
STEPWISE Parkinson: A Smartphone Based Exercise Solution for Patients With Parkinson's Disease
We'll reach out to this number within 24 hrs